Biomerica (NASDAQ:BMRA) (NASDAQ:BMRA) is a life sciences company specializing in the development, manufacture and commercialization of in vitro diagnostic tests and medical devices. The company’s core business activities encompass gastrointestinal health, diabetes management, cardiovascular wellness and cancer risk assessment. Biomerica’s product portfolio includes immunoassay kits, point-of-care analyzers, test strips and reagent sets that support early detection and monitoring of chronic and acute health conditions.
Founded in 1976 and headquartered in Irvine, California, Biomerica has grown from a regional diagnostics supplier into a global provider with distribution channels spanning North America, Europe, Latin America and Asia. The company maintains quality management systems in compliance with ISO 13485 standards, and many of its products carry CE marking for sale in the European Union. Biomerica’s manufacturing operations leverage partnerships with contract manufacturers in Asia and Europe to ensure scalability and cost efficiency.
Among its flagship offerings are gastrointestinal marker tests designed to detect conditions such as celiac disease, Helicobacter pylori infection and pancreatic insufficiency. Biomerica also markets rapid glucose and ketone monitoring strips, cardiac risk panels for home and clinical settings, and novel cancer screening assays aimed at early identification of colorectal and prostate malignancies. Through ongoing research collaborations, the company invests in next-generation diagnostics, including molecular and point-of-care platforms.
Biomerica is led by an executive team with extensive experience in diagnostics and medical device industries. Under the direction of its Chief Executive Officer, the company pursues strategic partnerships and expansion initiatives to broaden its product reach and enhance clinical utility. Biomerica continues to focus on innovation, regulatory compliance and customer support to address evolving healthcare needs around the world.
